Prevalence of cannabis use among tobacco smokers: a systematic review protocol

Eliza Skelton, Jane Rich, Tonelle Handley, Billie Bonevski

ABSTRACT

Introduction Understanding the prevalence of cannabis use among tobacco smokers has important implications for research in terms of intervention effectiveness and measurement in smoking cessation trials. The co-use of these substances also has important implications for health service planning, specifically ensuring appropriate and adequate clinical treatment. To date, there has been no synthesis of the literature on the prevalence of tobacco and cannabis co-use in adult clinical populations. Improved understanding of the current prevalence, route of administration and specific subpopulations with the highest rates of tobacco and cannabis co-use will support future intervention development. We aim to provide a pooled estimate of the percentage of smokers who report using cannabis and to examine the prevalence of co-use by sociodemographic characteristics.

Methods and analysis We will conduct a systematic review using six scientific databases with published articles from 2000 to 2022 inclusive (CENTRAL, CINAHL, EMBASE, Medline, PsycINFO, Psychology and Behavioural Sciences Collection, Scopus). Peer-reviewed journal articles published in English that report on tobacco and cannabis use will be included. Rates of co-use (simultaneous or sequentially) and routes of administration will be assessed. Use in populations groups will be described. Quality assessments will be conducted for all included studies. Data will be synthesised using a narrative approach. This study will be conducted from June 2022 to the end of August 2022.

Ethics and dissemination This review is based on previously published data and, therefore, ethical approval or written informed consent will not be required. It is the intention of the research team to disseminate the results of the systematic review as a peer-reviewed publication and conference presentations.

PROSPERO registration number CRD42020194051.

INTRODUCTION

Tobacco smoking continues to be a leading cause of preventable disease and death. An estimated 1.1 billion people continue to smoke tobacco. Over the past three decades, the prevalence of tobacco smoking has been increasing in low-income and middle-income countries (LMICs) where an inverse relationship is seen in high-income countries (HICs) where significant declines are noted.

For example, in LMIC, the adult smoking prevalence rate has increased from 12.4% to 22.8% in Rwanda, from 33.8% to 39.5% in Indonesia, and from 16% to 40.4% in Zambia. While in HIC, the tobacco smoking prevalence has reduced from 30.1% to 13.7% in the USA, from 31% to 14.0% in Australia, 30% to 14.2% in New Zealand and 33% to 14.1% in the UK. The decline in the prevalence of tobacco smoking appears to be less apparent among specific subpopulations in HIC. People who have a substance use disorder or are in treatment for substance misuse, people with a severe mental illness, people who are homeless or at risk of homelessness are found to have smoking rates 2–6 times higher than the general population.

Cannabis is another commonly used substance. Global estimates suggest that the number of cannabis users has increased in many countries, as has the treatment for cannabis use disorder. Changing regulatory environments and the legalisation of cannabis in some countries, and decreasing perceptions of risk associated with cannabis use, have been viewed to contribute to this recently increase in use. Other contributors to the increased use of cannabis include sociodemographic and environmental risk factors, including the COVID-19 pandemic. These factors may differ in...
between LMIC compared with HICs yet no review to date has examine this relationship.

Co-use can refer to concurrent use of both tobacco and cannabis, individually (sequentially), and to coadministration, or the use of the two substances at the same time, for example, cannabis and tobacco leaf mixed within roll-your-own cigarettes (concurrent).\textsuperscript{20} Patterns of tobacco and cannabis co-use appear to differ by country. A 2018 International Tobacco Control Survey identified that Canada, followed by the USA (29.1%), England (21.6%) and Australia (21.4%) had the highest rates of tobacco and cannabis co-use.\textsuperscript{21} There are limited studies examining tobacco and cannabis co-use in LMIC. Tobacco and cannabis co-use is often missed in population prevalence surveys.\textsuperscript{23}

Previous reviews on tobacco and cannabis co-use have examined mechanisms of initiation,\textsuperscript{22 23} toxicant exposure,\textsuperscript{24} and coadministered products (such as blunts or spliffs).\textsuperscript{25} While other reviews have focused specifically on certain populations such as adolescents and young adults,\textsuperscript{26} Lemry et al.\textsuperscript{27} in their review, detail the motivation and drivers of co-use including gateway theory and reverse gateway which may have implications in understanding co-use and interventions for cessation.

A recent review did explore treatment implications for those that co-use tobacco and cannabis,\textsuperscript{28} highlighting the challenges of single substance cessation and noting that interventions to address co-use cessation are lacking. Another, important gap in the growing literature is a comprehensive pooled prevalence estimate of tobacco and cannabis co-use. Synthesising existing data including correlates of use\textsuperscript{29} is important to understand the extent to which tobacco and cannabis co-use is occurring.

There appears to be an increased physiological effect of both substance when used together. The mechanisms underlying the co-use of tobacco and cannabis have been identified as shared genetic factors, environmental factors (peer influences; availability; younger age), and economic factors (lower socio-economic factors).\textsuperscript{22,26} More recently, another possible factor influencing co-use of tobacco and cannabis is the common route of administration, for example, smoking/inhalation of both substances.\textsuperscript{20} To date, only one review has examined route of administration and only focused on combustible forms of tobacco and cannabis co-use.\textsuperscript{25} A synthesis of the literature that includes all possible routes of administration would fill this gap in the literature.

Compared with other substances, cannabis use among tobacco smokers appears to be more common than the co-use of other substances that occur at a remarkably reduced rate such as alcohol (33.3%–45.7%), cocaine (37.5%–42.9%), stimulants (30%–51.7%) and hallucinogens (35.6%–41.7%).\textsuperscript{30–32} The relationship between tobacco and cannabis use is synergistic in that tobacco use increases cannabis dependence symptoms\textsuperscript{30 31,33} and precipitates cannabis relapse\textsuperscript{34} and similarly cannabis use increases the likelihood of nicotine dependence\textsuperscript{30 31,33} and decreases tobacco cessation.\textsuperscript{36} Given this, people who co-use both tobacco and cannabis are at greater risk for serious for serious health and psychosocial problems.\textsuperscript{23} Co-use is associated with increased risks of toxicant exposure, poorer physical and mental functioning.\textsuperscript{25}

Understanding and accounting for current cannabis use among participants involved in smoking cessation research is important as it may have an impact on the intervention effect but also the measurement effect. If smokers are recruited into a smoking cessation intervention but their cannabis use is not addressed, then relapse to tobacco smoking is likely if they regularly mixed their tobacco with cannabis. Similarly, since cannabis use is detected in carbon monoxide breath analysis, this method of biochemical verification of tobacco smoking status may be inaccurate. Therefore, an alternate biochemical method such as serum or salivary cotinine may be preferable for self-reported tobacco smokers who use cannabis.\textsuperscript{37}

Only limited research has described the demographic and clinical characteristics of people who use both tobacco and cannabis. These studies predominately focused on young people who use these substances. Demographic characteristics such as older adolescents\textsuperscript{38 39} another found that people who co-use tobacco and cannabis were younger than tobacco-only users,\textsuperscript{26} of male gender and ethnicity. A synthesis of the current literature is critical for the development of an evidence base foundation for developing future randomised controlled trials. This review will provide the first synthesis of the literature and provide pivotal information for specific countries to influence the development of socially and culturally appropriate interventions to further the evidence base.

There is a clear need for an improved understanding as to the co-use of tobacco and cannabis use as this will have practical implications in the design of smoking cessation studies. The tiered approach of assessing co-use as explained by Hindocha and McClure\textsuperscript{40} suggests that consideration of individual-use data as well as co-use data be explored as often there is a lack of nuance in the current methods of collection and analysis. Our review will ask the following questions. (1) What is the percentage of smokers who report also using cannabis; (2) What is the nature of co-use of tobacco and cannabis (eg, mixing together or smoking at different times, including routes of administration) and (3) What is the prevalence of co-use tobacco and cannabis by sociodemographic characteristics (age; gender; country—low and high income; clinical characteristics such as mental health diagnosis and substance use disorder).

**METHODS**

**Study design**

We will complete a systematic review examining the prevalence of cannabis use among tobacco smokers generally and by specific sociodemographic and clinical characteristics as well as the nature of the use of these substances (whether concurrently or individually). This review will be conducted in line with the Preferred Reporting Items
for Systematic Reviews and Meta-analyses guidelines with
data managed using Stata 15 Statistical Software.41

Study criteria

Study designs
We will include the following study designs: cohort, cross-sectional, observational, baseline studies, national reports. We will exclude published editorials, letters or conference proceedings (including abstracts), qualitative studies, thesis dissertations and studies quoting the incidence rate rather than prevalence. Further, we will not use genetic epidemiological studies that report prevalence estimates in family members of individuals who use tobacco and cannabis. This study will be conducted from June 2022 to the end of August 2022.

Study populations and participants
Person-level data will be included from any adult population (aged >18 years and older) including but not limited to educational populations (eg, university populations), forensic or correctional populations, treatment seeking populations (people receiving treatment for substance use disorders or mental health conditions, oncological conditions and other chronic diseases). We will include all routes of administration of tobacco use including alternate nicotine devices such as vapourisers.

Outcomes
We will include studies that report primary data on the prevalence of tobacco and cannabis use (such as total number of participants and percentages or proportions). Given that there is no standard assessment tool of tobacco and cannabis co-use we will include all measures as documented in the literature. For example, separate items that measure cannabis and tobacco use: ‘Do you currently smoke any tobacco products?’ with response options (1) yes, at least once a week; (2) yes, less often than once week; (3) no, not at all; ‘During the past 30 days, on how many days did you use cannabis?’; ‘How many times is cannabis used per day on using days’. Co-use has been defined in several recent US studies as the use of both substances within the past 30 days.

Additional eligibility criteria
Only articles that are published in English and that have been published in peer reviewed journals will be included.9

Ethics and dissemination
This review is based on previously published data and therefore ethical approval or written informed consent will not be required. It is the intention of the research team to disseminate the results of the systematic review as a peer reviewed publication and conference presentations.

Search strategy
The search will be conducted in six databases with published articles from 2000 to 2022 inclusive: CENTRAL, CINAHL, EMBASE, Medline, PsycINFO, Psychology and Behavioural Sciences Collection, Scopus, using keywords consistent across all databases and Medical Subject Headings (MeSH) applicable to specific databases. The Medline search terms are outlined in Table 1. Each search term is related to an overarching theme that map largely to the review aims (tobacco use and cannabis use). It should be noted that the search terms have been developed with guidance from the Cochrane Public Health and Tobacco Addiction Group search terms.

Screening
Two research assistants (AD, AL) will screen all titles and abstracts using the previously described inclusion criteria overseen by the research academics (ES, JR, TH). Any disagreements will be discussed. If a resolution cannot be found, the senior review author (BB) will hold a discussion until a resolution is found. The two RAs (AD, AL) completing 50% each. Again, any disagreements will be discussed between the authors and the research assistants. All title, abstract, and full-text data screening will be completed using the Covidence online software V.1919 73d6c782.

Data extraction
The team will develop a data extraction form based on the aims of the study. The data extraction form will include: country, year of publication, author, sample size, gender, tobacco use prevalence (lifetime, last 12 months, current), cannabis use prevalence (lifetime, last 12 months, current), co-use prevalence and routes of administration will be extracted for each paper. The co-use prevalence and calculated 95% CIs for each estimate will be extracted. For papers reporting measures over time, we will use the prevalence data from the baseline assessment. Two post-doctoral research academics (ES and JR) will

---

Table 1

| Theme              | Search terms                                                                 | Limitations                   |
|--------------------|-----------------------------------------------------------------------------|-------------------------------|
| Study design       | Epidemiology OR Cohort analysis OR Cross-sectional analysis OR Observational analysis OR Prevalence OR Longitudinal | 2000–2022                     |
| Tobacco use        | tobacco OR nicotine OR smok* OR vap* OR cigar*                              | Exclude clinical trials       |
| Cannabis use       | cannabis OR cannabinoid* OR marijuana OR weed OR hash*                      |                               |
extract data from all included publications. Any disagreements will be discussed between all authors. If a resolution cannot be found, the senior review author (BB) will be consulted in order to determine a resolution. Data will be extracted using the Covidence software.

Quality assessment
All cohort, cross-sectional and case–control studies will be appraised according to Newcastle-Ottawa Quality Assessment Scale for cohort and case–control studies (adapted for cross-sectional studies). Using the tool each study is judged on eight items, that can be categorised into three further groups: (1) The selection of the study groups, (2) The comparability of the groups and (3) The ascertainment of either the exposure or outcome of interest for case–control or cross-sectional studies respectively. Articles will not be excluded based on their score on the quality appraisal tool. Quality scores will guide judgement of the methodological quality of the trial and reliability of the findings.

The risk of bias (quality) of all studies meeting the inclusion criteria will be formally assessed by ES, JR and TH. Disagreements will be resolved by discussion with the senior review author (BB). Ratings will be presented in a table and will be used to inform the narrative synthesis.

Assessment of study heterogeneity
Heterogeneity will be examined using visual inspection of box plots, forest plots and using the $I^2$ statistic, Egger’s test will be applied.42 Where there is evidence of high heterogeneity ($I^2>75\%$), heterogeneity will be explored via subgroup analyses according to population characteristics. If the heterogeneity among the studies is large, a random-effects model will be used to calculate the pooled OR. Otherwise, a fixed-effects model will be applied. We will use a generalised linear model approach, due to methodological concerns with the Freeman-Tukey double-arcsine transformation method.43 44 Funnel plots will be generated by statistical software to enable the assessment of publication bias. If publication bias is detected, the approximate number of missing studies using the trim-and-fill method45 will be conducted to provide insight into degree of bias.

Grading the strength of evidence
As recommended by the Cochrane Handbook for Systematic Reviews of Interventions, the overall quality of evidence of the outcomes (tobacco and cannabis co-use prevalence) will be presented using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. This involves a within-study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias. The overall quality of evidence will be rated at four levels: high, moderate, low and very low. If feasible, the analysis could include individual participant-level meta-analysis.

ES and JR will assess the quality of evidence using the GRADE tool and will present the findings to the fellow authors. The team will discuss the assessment and modify the reported strength of recommendations.

Data synthesis
Depending on the outcome measure employed by studies, pooled estimates by lifetime use, 12 months and current use will be calculated. If studies have used similar definitions and measures, cannabis prevalence plots including the associated confidence intervals for each study will be presented. If there are national prevalence estimates for cannabis use, we will examine the difference between the study and the national prevalence.

In order to obtain the national smoking prevalence rates, official country statistics websites and the WHO Health Observatory Data Repository46 will be consulted and the prevalence data extracted. If the national cannabis prevalence estimates are not available for all included countries for all years in which included studies were completed, we will report this information descriptively in the results section.

Included studies will be examined by sociodemographic and clinical characteristics to provide individual prevalence estimates and distributions. These will include sociodemographic characteristics such as age, gender, country, nationality and indigeneity. These will also include clinical characteristics such as mental health diagnosis as per the clinical diagnostic handbooks and tools (such as the Diagnostic and Statistical Manual of mental disorders47 or the International Classification of Disease (ICD)48) including substance use disorders and clinical populations such as individuals receiving treatment from addiction treatment or mental health services, as well as those with cardiovascular disease, diabetes or cancer.

Patient and public involvement
No patients involved.

Study status
At the time of submission of this protocol, the authors had completed screening of titles, abstracts and full texts, and were beginning data extraction and quality assessment.

DISCUSSION
The co-use of tobacco and cannabis and the subpopulation who are most likely to co-use these substances are important considerations for intervention planning. This systematic review will provide pooled prevalence estimates of cannabis use among tobacco smokers. This study will report on tobacco and cannabis co-use by specific sociodemographics and clinical characteristics to provide a more in-depth examination and synthesis of the available data. This study will also provide the routes of administration of tobacco and cannabis co-use as this is an important aspect when developing behavioural interventions for cessation. As with all research, naturally
there are limitations to be considered. First, is publication bias, it is likely that given the rigorous nature of predeter-
mined search strategies some publications may be missed from this review. Second, is that if the included studies
measures are too heterogeneous, a complete a meta-
analysis may not be feasible. However, in using the gold
standard of meta-analysis, the proposed review will collate
multiple studies to provide the first pooled prevalence of
tobacco and cannabis co-use. This review will also provide
important information on the subgroups that require
targeted intervention. As such, the benefits of this review
will outweigh any such methodological limitations.

Acknowledgements

Research Assistance thanks to Alexandra Denham and Alexie
Lye for their database assistance and screening abstract reviews.

Contributors

ES, JR and TH developed the protocol and drafted the manuscript. BB
reviewed drafts and provided methodological feedback and guidance. All authors
approved the final manuscript.

Funding

The authors have not declared a specific grant for this research from any
funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Patient and public involvement

Patients and/or the public were not involved in the
design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication

Not applicable.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open access

This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, provided the original work is properly cited, appropriate credit is given, any changes made indicated,
and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Eliza Skelton http://orcid.org/0000-0003-1087-5305

REFERENCES

1 Anderson CL, Becher H, Winkler V. Tobacco control progress in low
and middle income countries in comparison to high income
countries. Int J Environ Res Public Health 2016;13:1039.
2 Brathwaite R, Addo J, Smeeth L, et al. A systematic review of
tobacco smoking prevalence and description of tobacco control
strategies in sub-Saharan African countries; 2007 to 2014. PLoS One
2015;10:e0132401.
3 Centers for Disease Control and Prevention. Smoking & Tobacco
Use: Current Cigarette Smoking among Adults in the United States,
2020. Available: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm
4 Australian Institute of Health and Welfare. National Drug Strategy
Household Survey 2019, 2019. Available: https://www.aihw.gov.au/
reports/illicit-use-of-drugs/national-drug-strategy-household-survey-
2019/contents/table-of-contents
5 New Zealand Ministry of Health. Key indicators 2020, 2020.
Available: https://minhealthnz.shinyapps.io/nz-health-survey-2018-
19-annual-data-explore/_w_262657b5/#/key-indicators
6 United Kingdom Government. Adult smoking habits in the UK: 2019,
2020. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifefeelexpectancies/bulletins/adultsni smokinghabitsinbritain2019/characteristics-of-current-cigarettesmokers-in-the-uk
7 Bonevski B, Borland R, Paul CL, et al. No smoker left behind: it’s
time to tackle tobacco in Australian priority populations. Med J Aust
2017;207:141–2.
8 Guichard J, Passalacqua E, Pagano A, et al. An international
systematic review of smoking prevalence in addiction treatment.
Addiction 2016;111:220–30.
9 Dickerson F, Stallings CR, Ongioni AE, et al. Cigarette smoking
among persons with schizophrenia or bipolar disorder in routine
clinical settings, 1999-2011. Psychiatr Serv 2013;64:44–50.
10 Arnsten JH, Reid K, Bierer M, et al. Smoking behavior and interest in
quitting among homeless smokers. Addict Behav 2004;29:1155–61.
11 World Health Organization. The health and social effects of
nonmedical cannabis use, 2021. Available: https://www.who.int/
tobaccobulletins/publications/msbcannabis.pdf
12 Degenhardt L, Ferrari AJ, Calabria B, et al. The global epidemiology
and contribution of cannabis use and dependence to the global
burden of disease: results from the GBD 2010 study. PLoS One
2013;8:e76635.
13 Weineberger AH, Pacek LR, Wall MM, et al. Cigarette smoking quit
ratios among adults in the USA with cannabis use and cannabis use
disorders, 2002-2016. Tob Control 2020;29:74–80.
14 Weineberger AH, Pacek LR, Wall MM, et al. Trends in cannabis use
disorder by cigarette smoking status in the United States, 2002-
2016. Drug Alcohol Depend 2018;181:45–51.
15 Maxwell JC, Mendelson B. What do we know now about the impact
of the laws related to marijuana? J Addict Med 2016;10:3–12.
16 Mauro CM, Newsomperger P, Santaela-Tenorio J, et al. Impact of
medical marijuana laws on state-level marijuana use by age and
gender, 2004-2013. Prev Sci 2019;20:205–14.
17 Pacek LR, Mauro PM, Martins SS. Perceived risk of regular cannabis
use in the United States from 2002 to 2012: differences by sex, age,
and race/ethnicity. Drug Alcohol Depend 2015;149:232–44.
18 Swendsen J, Conway KP, Degenhardt L, et al. Socio-demographic
risk factors for alcohol and drug dependence: a 10-year follow-
up of the national comorbidity survey. Addiction 2009;104:1346–55.
19 Zajacova A, Jehn A, Stockhouse M, et al. Changes in health
behaviours during early COVID-19 and socio-demographic
disparities: a cross-sectional analysis. Can J Public Health
2020;111:653–62.
20 Agrawal A, Lynskey MT. Tobacco and cannabis co-occurrence: does
route of administration matter? Drug Alcohol Depend 2009;99:240–7.
21 Gravely S, Driessen P, Smith DM, et al. International differences in
patterns of cannabis use among adult cigarette smokers: findings from
the 2018 ITC four country smoking and vaping survey. Int J Drug
Policy 2020;79:102754.
22 Agrawal A, Budney AJ, Lynskey MT. The co-occuring use and
misuse of cannabis and tobacco: a review. Addiction
2012;107:2231–33.
23 Rabin RA, George TP. A review of co-morbid tobacco and cannabis use
disorders: possible mechanisms to explain high rates of co-use.
Am J Addict 2015;24:105–16.
24 Meier E, Hatsukami DK. A review of the additive health risk of
cannabis and tobacco co-use. Drug Alcohol Depend 2016;166:6–12.
25 Schauer GL, Rosenberg ZR, Peters EN. Marijuana and tobacco co-
administration in blunts, spliffs, and mulled cigarettes: a systematic
literature review. Addict Behav 2017;64:200–11.
26 Ramo DE, Liu H, Prochaska JJ. Tobacco and marijuana use among
adolescents and young adults: a systematic review of their co-use.
Clin Psychol Rev 2012;32:105–21.
27 Lemyre A, Poliakova N, Bélanger RE. The relationship between
tobacco and cannabis use: a review. Subst Use Misuse
2019;54:130–45.
28 McClure EA, Rabin RA, Lee DC, et al. Treatment implications
associated with cannabis and tobacco Use-Curr Addict Rep
2020;7:533–44.
29 Peters EN, Budney AJ, Carroll KM. Clinical correlates of co-
occurring cannabis and tobacco use: a systematic review. Addiction
2012;107:1404–13.
30 Barrett SP, Darredez C, Pihl RO. Patterns of simultaneous
polysubstance use in drug using university students. Hum
Psychopharmacol 2006;21:255–63.
31 Richter KP, Ahluwalia HK, Mosier MC, et al. A population-based
study of cigarette smoking among illicit drug users in the United
States. Addiction 2002;97:861–9.
32 Correa JB, Myers MG, Tully LK, et al. Co-Occurring use of cannabis
and tobacco and the presence of acute respiratory symptoms
among young adult light and intermittent smokers. Subst Use
Misuse 2020;55:2129–47.
33 Ream GL, Benot E, Johnson BD, et al. Smoking tobacco along
with marijuana increases symptoms of cannabis dependence. Drug
Alcohol Depend 2008;95:199–208.
34 Haney M, Bedi G, Cooper ZD, et al. Predictors of marijuana relapse
in the human laboratory: robust impact of tobacco cigarette smoking
status. Biol Psychiatry 2013;73:242–8.
35 Okoli CTC, Richardson CG, Ratner PA, et al. Adolescents’ self-defined
tobacco use status, marijuana use, and tobacco dependence. Addict Behav 2008;33:1491–9.
36 Ford DE, Vu HT, Antony JC. Marijuana use and cessation of
tobacco smoking in adults from a community sample. Drug Alcohol
Depend 2002;67:243–8.
37 van Vunakis H, Tashkin DP, Rigas B, et al. Relative sensitivity and specificity of salivary and serum cotinine in identifying tobacco-smoking status of self-reported nonsmokers and smokers of tobacco and/or marijuana. *Arch Environ Health* 1989;44:53–8.

38 Suris JC, Akre C, Berchtold A, et al. Some go without a cigarette: characteristics of cannabis users who have never smoked tobacco. *Arch Pediatr Adolesc Med* 2007;161:1042–7.

39 Victoir A, Eertmans A, Van den Bergh O, et al. Association of substance-use behaviours and their social-cognitive determinants in secondary school students. *Health Educ Res* 2007;22:81–94.

40 Hindocha C, McClure EA. Unknown population-level harms of cannabis and tobacco co-use: if you don’t measure it, you can’t manage it. *Addiction* 2021;116:1622–30.

41 StataCorp L. *Stata statistical software: Release 15*. College Station, TX: StataCorp LP, 2017.

42 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.

43 Schwarzer G, Chemaitelly H, Abu-Raddad LJ, et al. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. *Res Synth Methods* 2019;10:476–83.

44 Lin L, Xu C. Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives. *Health Sci Rep* 2020;3:e178.

45 Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455–63.

46 World Health Organization. *Global health observatory data repository*, 2013.

47 Association, A.P. *Diagnostic and statistical manual of mental disorders (DSM-5®)*. American Psychiatric Pub, 2013.

48 World Health Organization. *International Classification of Disease—Ninth revision (ICD-9)*. *Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire* 1988;63:343–4.